ReviewTouchREVIEWS in endocrinology2026
Balancing clinical benefits and behavioral risks of obesity-focused management in youth-onset type 2 diabetes: A narrative review.
Review in TouchREVIEWS in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Weight management is a key treatment goal for youth-onset type 2 diabetes, a condition that is strongly linked with obesity. For this reason, glucagon-like peptide-1 (GLP-1) receptor agonists, with their glycemic- and weight-reducing effects, have been increasingly used in adolescents and young adults with type 2 diabetes. However, because disordered eating behaviors and eating disorders are also relatively common in this population, use of appetite-suppressing medications such as GLP-1 may have unintended psychological or behavioral consequences. In this narrative review, we summarize the epidemiology of disordered eating behaviors and eating disorders among youth with type 2 diabetes and the limited evidence related to disordered eating and GLP-1 use. We end with suggested strategies for clinicians to identify and care for youth with disordered eating behaviors or eating disorders in the context of type 2 diabetes. Future research should prioritize the creation and validation of a disordered eating screener that is appropriate for youth with type 2 diabetes undergoing medical weight management, as well as identify factors associated with positive versus negative eating behavior responses to GLP-1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.